Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityNon-Current DebtOther Non-Current LiabilitiesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Goldenwell Biotech (GWLL) Current Deferred Revenue (2022 - 2025)

Goldenwell Biotech (GWLL) has disclosed Current Deferred Revenue for 4 consecutive years, with $37500.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Deferred Revenue rose 3030.22% year-over-year to $37500.0, compared with a TTM value of $37500.0 through Sep 2025, up 3030.22%, and an annual FY2023 reading of $1914.0, up 35.74% over the prior year.
  • Current Deferred Revenue was $37500.0 for Q3 2025 at Goldenwell Biotech, up from $1860.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $37500.0 in Q3 2025 and bottomed at $1198.0 in Q1 2024.
  • Average Current Deferred Revenue over 4 years is $4760.7, with a median of $1410.0 recorded in 2022.
  • The sharpest move saw Current Deferred Revenue decreased 15.04% in 2024, then soared 3030.22% in 2025.
  • Year by year, Current Deferred Revenue stood at $1410.0 in 2022, then surged by 35.74% to $1914.0 in 2023, then crashed by 37.41% to $1198.0 in 2024, then skyrocketed by 3030.22% to $37500.0 in 2025.
  • Business Quant data shows Current Deferred Revenue for GWLL at $37500.0 in Q3 2025, $1860.0 in Q2 2025, and $1860.0 in Q1 2025.